Related Experiment Videos
Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors
N Kimura1, M Pilichowska, F Date
1Department of Pathology, Tohoku University School of Medicine, and Tohoku Rosai Hospital, Sendai, Japan. nkimura@patholo2.med.tohoku.ac.jp
Abstract:
Somatostatin (SS) and SS analogues inhibit the growth of various kinds of endocrine and exocrine cells via the SS receptor (SSTR). Carcinoid tumor is representative of the tumors treatable by SS analogues. We examined the expression of SSTR2A by immunohistochemical and in situ hybridization methods with a specific antibody against a synthesized 20-amino acid peptide of the COOH terminus of human SSTR2A and oligonucleotide probes in 62 endocrine tumors of various kinds: pancreatic endocrine tumor; carcinoid; neuroendocrine carcinoma; medullary thyroid carcinoma; pheochromocytoma; and small cell carcinoma of the lung, neuroblastoma, and ganglioneuroma. SSTR2A was expressed in 87% of these tumors and at both primary and metastatic sites. The immunohistochemical reactivity of SSTR2A was strong on the cell membrane and less intense in the cytoplasm of the tumor cells. SSTR2A mRNA was also detected in the tumor cells. The results indicate the usefulness of SSTR2A analogues for the treatment of neuroendocrine tumors, even metastatic ones: metastatic carcinoids, metastatic pheochromocytomas, tumors that adhered to large vessels, and neuroendocrine carcinomas.
Insights
Somatostatin receptor 2A (SSTR2A) is widely expressed in neuroendocrine tumors, including metastatic types. This finding supports the use of SSTR2A analogues for treating these challenging cancers.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Somatostatin (SS) and its analogues are known to inhibit endocrine and exocrine cell growth through the SS receptor (SSTR).
- Carcinoid tumors are a key example of neoplasms responsive to SS analogue therapy.
Purpose of the Study:
- To investigate the expression of Somatostatin Receptor Subtype 2A (SSTR2A) in a variety of human neuroendocrine tumors.
- To determine the potential of SSTR2A as a therapeutic target for neuroendocrine neoplasms.
Main Methods:
- Immunohistochemistry (IHC) using a specific antibody against human SSTR2A.
- In situ hybridization (ISH) employing oligonucleotide probes to detect SSTR2A mRNA.
- Analysis of 62 diverse neuroendocrine tumors, including pancreatic endocrine tumors, carcinoids, and small cell lung carcinoma.
Main Results:
- SSTR2A expression was detected in 87% of the evaluated neuroendocrine tumors.
- Expression was confirmed at both primary and metastatic tumor sites.
- Immunohistochemical staining showed strong SSTR2A reactivity on the cell membrane and weaker cytoplasmic staining, with corresponding mRNA detection.
Conclusions:
- The widespread expression of SSTR2A in neuroendocrine tumors, including metastatic forms, highlights its potential as a therapeutic target.
- SSTR2A analogues demonstrate significant promise for treating a range of neuroendocrine neoplasms, such as metastatic carcinoids and pheochromocytomas.